the of divergence between and on the to suitable by focusing on the F and HN proteins. Comparative bioinformatics analyses based on B- and T-cell epitopes binding affinity, protein secondary structure and physicochemical properties predictions were applied for genotypes II and VII. Results: Although the results showed more differences in HN protein than F protein, there was no major difference between the predicted antigenicity values, epitope regions, affinity binding to MHC-I and MHC-II, secondary structures, surface accessibility, and stability of these immunogens between genotypes II and VII. Conclusion: The results suggest that genotype II-based live vaccines can induce immune responses against NDV; however, an inactivated vaccine formulated by genotype VII should be considered in combination with the traditional live vaccine to provide better protection in controlling programs against ND.
{"title":"The predominance of Newcastle disease virus genotype VII: genome diversity or poor cross-immunity of non-matched vaccines","authors":"S. Shahsavandi, M. Ebrahimi, Majid Tebianain","doi":"10.52547/vacres.8.2.4","DOIUrl":"https://doi.org/10.52547/vacres.8.2.4","url":null,"abstract":"the of divergence between and on the to suitable by focusing on the F and HN proteins. Comparative bioinformatics analyses based on B- and T-cell epitopes binding affinity, protein secondary structure and physicochemical properties predictions were applied for genotypes II and VII. Results: Although the results showed more differences in HN protein than F protein, there was no major difference between the predicted antigenicity values, epitope regions, affinity binding to MHC-I and MHC-II, secondary structures, surface accessibility, and stability of these immunogens between genotypes II and VII. Conclusion: The results suggest that genotype II-based live vaccines can induce immune responses against NDV; however, an inactivated vaccine formulated by genotype VII should be considered in combination with the traditional live vaccine to provide better protection in controlling programs against ND.","PeriodicalId":52727,"journal":{"name":"Vaccine Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42122117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sinopharm (BBIBP -CorV) is an inactivated whole -virus COVID -19 vaccine. The phase 3 trial showed an efficacy of up to 78% in preventing symptomatic COVID -19 infections. However, there have been questions raised regarding in its efficacy in older people. In this paper, several pertaining lessons are highlighted. Firstly, there is a need to take into account the heterogeneity of COVID -19 vaccine studies, such as representation of older people;and whether the results are generalizable to the target population of immunization programs. Secondly, for older people, antibody responses alone may not indicate the level of protection provided by the vaccines, as cell mediated immunity is a better determinant of immunity in this age group. Finally, suggestions are given to improve the immune responses in older people, such as heterologous vaccination and booster doses.
{"title":"Lessons Learned from Global Administration of Sinopharm (BBIBP-CorV) Vaccine and Its Efficacy against COVID-19 in Older People","authors":"S. Teo","doi":"10.52547/vacres.8.2.1","DOIUrl":"https://doi.org/10.52547/vacres.8.2.1","url":null,"abstract":"Sinopharm (BBIBP -CorV) is an inactivated whole -virus COVID -19 vaccine. The phase 3 trial showed an efficacy of up to 78% in preventing symptomatic COVID -19 infections. However, there have been questions raised regarding in its efficacy in older people. In this paper, several pertaining lessons are highlighted. Firstly, there is a need to take into account the heterogeneity of COVID -19 vaccine studies, such as representation of older people;and whether the results are generalizable to the target population of immunization programs. Secondly, for older people, antibody responses alone may not indicate the level of protection provided by the vaccines, as cell mediated immunity is a better determinant of immunity in this age group. Finally, suggestions are given to improve the immune responses in older people, such as heterologous vaccination and booster doses.","PeriodicalId":52727,"journal":{"name":"Vaccine Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47395302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Maryam Mashhadi Abolghasem Shirazi, A. Arashkia, S. Haghighat, F. Roohvand, S. M. Sadat
against using tools. Methods: The HPV16 RG-1 epitope linked to built-in adjuvants including the D1 domain of flagellin as agonists, and a tetanus toxoid epitope for induction of immune responses. Using immunoinformatic tools, the immunological characteristics of the construct were evaluated. In the first step, MHC-I and II binding, CD4 + T cell immunogenicity prediction, and in the second step, immunogenicity simulation of the construct were investigated. Results: MHC-I and II predicted epitopes showed a high potentiality to bind to mice and human MHC alleles. The results of the binding of the RG-1 epitope to MHC-I and MHC-II showed that RG1 could induce humoral and cellular immune response while fused to three built-in adjuvants. Also, the CD4 + immunogenicity assessment results predicted that several epitopes in the designed construct, including epitopes of D1 domain and tetanus toxoid P2 epitope, behaved as potentially strong Th inducers. The immunogenicity simulation results showed that the construct could potentially provide sufficient antigen, and induce suitable humoral and cellular immune responses. Conclusion: The development of new vaccine strategies has been the focus of several studies. The results showed that the designed construct can potentially provide an effective model for developing a preventive vaccine candidate against a variety of HPV genotypes.
{"title":"Immunoinformatics Approach for Designing an HPV Epitope-Based Vaccine Candidate Harboring Built-in Adjuvants","authors":"Maryam Mashhadi Abolghasem Shirazi, A. Arashkia, S. Haghighat, F. Roohvand, S. M. Sadat","doi":"10.52547/vacres.8.2.28","DOIUrl":"https://doi.org/10.52547/vacres.8.2.28","url":null,"abstract":"against using tools. Methods: The HPV16 RG-1 epitope linked to built-in adjuvants including the D1 domain of flagellin as agonists, and a tetanus toxoid epitope for induction of immune responses. Using immunoinformatic tools, the immunological characteristics of the construct were evaluated. In the first step, MHC-I and II binding, CD4 + T cell immunogenicity prediction, and in the second step, immunogenicity simulation of the construct were investigated. Results: MHC-I and II predicted epitopes showed a high potentiality to bind to mice and human MHC alleles. The results of the binding of the RG-1 epitope to MHC-I and MHC-II showed that RG1 could induce humoral and cellular immune response while fused to three built-in adjuvants. Also, the CD4 + immunogenicity assessment results predicted that several epitopes in the designed construct, including epitopes of D1 domain and tetanus toxoid P2 epitope, behaved as potentially strong Th inducers. The immunogenicity simulation results showed that the construct could potentially provide sufficient antigen, and induce suitable humoral and cellular immune responses. Conclusion: The development of new vaccine strategies has been the focus of several studies. The results showed that the designed construct can potentially provide an effective model for developing a preventive vaccine candidate against a variety of HPV genotypes.","PeriodicalId":52727,"journal":{"name":"Vaccine Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41678483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Introduction: Although, conventional methods for the expression of polyomaviruses and herpesviruses recombinant proteins for serological assays and vaccine developments in baculoviruses are well established, the manipulations are laborious and time consuming. Methods: A new expression system based on plasmid was used to express two polyomaviruses major capsid protein VP1 (JCV VP1 and BKV VP1), and two herpesviruses glycoproteins (HSV-1 gD and VZV gE) in insect cells. A ligation independent cloning (LIC) was applied to generate the recombinant plasmids. Transfection of Sf9 insect cells were performed using the recombinants. The produced proteins were analysed using SDS-PAGE, immunofluorescence, and immunoblotting. Results: JCV-VP1, BKV-VP1, VZV-gE and HSV-1gD were successfully expressed in the insect cells, 48 h post-infection and detected in cytoplasm and cell membranes with immunoreactivity. This plasmid based expression system took 5 days to express the protein. Conclusion: The plasmid based expression system in insect cells was highly efficient and would be ideal for rapid expression of polyomaviruses and herpesviruses proteins in insect cells to be potentially used in applications such as vaccine components and serological assays.
{"title":"Production of Polyomavirus and Herpesvirus Recombinant Glycoproteins with Immunoreactivity Using a Rapid and Novel Expression System in Insect Cells for Applications in Vaccines and Serological Assays","authors":"B. Abedi Kiasari, H. Najafi","doi":"10.52547/vacres.8.1.67","DOIUrl":"https://doi.org/10.52547/vacres.8.1.67","url":null,"abstract":"Introduction: Although, conventional methods for the expression of polyomaviruses and herpesviruses recombinant proteins for serological assays and vaccine developments in baculoviruses are well established, the manipulations are laborious and time consuming. Methods: A new expression system based on plasmid was used to express two polyomaviruses major capsid protein VP1 (JCV VP1 and BKV VP1), and two herpesviruses glycoproteins (HSV-1 gD and VZV gE) in insect cells. A ligation independent cloning (LIC) was applied to generate the recombinant plasmids. Transfection of Sf9 insect cells were performed using the recombinants. The produced proteins were analysed using SDS-PAGE, immunofluorescence, and immunoblotting. Results: JCV-VP1, BKV-VP1, VZV-gE and HSV-1gD were successfully expressed in the insect cells, 48 h post-infection and detected in cytoplasm and cell membranes with immunoreactivity. This plasmid based expression system took 5 days to express the protein. Conclusion: The plasmid based expression system in insect cells was highly efficient and would be ideal for rapid expression of polyomaviruses and herpesviruses proteins in insect cells to be potentially used in applications such as vaccine components and serological assays.","PeriodicalId":52727,"journal":{"name":"Vaccine Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42987484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. Alamdary, A. Gholami, M. Azizi, Z. Noormohammadi
Methods: An additional glycoprotein gene of the rabies virus PV strain was inserted between the glycoprotein and polymerase genes of the virus. The viral proteins were expressed at the T7BHK cell line to rescue the recombinant virus. Results: The recombinant virus containing two consecutive glycoprotein genes was rescued from T7BHK cells. The virus particles were functional and successfully infected the permissive BSR cell line. Conclusion: The new virus strain with an additive copy of the glycoprotein gene has a good potential to be utilized in different studies, including cell biology and immunological properties of the rabies virus. In this study, the recombinant rabies virus was successfully rescued from cell culture which would way
{"title":"Construction and Rescue of a Rabies Virus with Duplicated Glycoprotein Gene","authors":"A. Alamdary, A. Gholami, M. Azizi, Z. Noormohammadi","doi":"10.52547/vacres.8.1.104","DOIUrl":"https://doi.org/10.52547/vacres.8.1.104","url":null,"abstract":"Methods: An additional glycoprotein gene of the rabies virus PV strain was inserted between the glycoprotein and polymerase genes of the virus. The viral proteins were expressed at the T7BHK cell line to rescue the recombinant virus. Results: The recombinant virus containing two consecutive glycoprotein genes was rescued from T7BHK cells. The virus particles were functional and successfully infected the permissive BSR cell line. Conclusion: The new virus strain with an additive copy of the glycoprotein gene has a good potential to be utilized in different studies, including cell biology and immunological properties of the rabies virus. In this study, the recombinant rabies virus was successfully rescued from cell culture which would way","PeriodicalId":52727,"journal":{"name":"Vaccine Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48611859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
This article provides an overview of cutaneous reactions after administration of COVID19 vaccines. Cutaneous reactions post COVID-19 trials range from acute and immediate reactions to delayed reactions. The suspected triggers for the hypersensitivity reactions are the inactive ingredients, such as polyethylene glycol in mRNA vaccines and polysorbate 80 in AstraZeneca. Localized or injection-site reactions are generally self-limiting and occur within seven days. Younger, female patients were more likely to report injection-site reactions. Cutaneous reactions after the second dose occurred earlier than after the first dose. Delayed large local reactions or „COVID arms‟ have been reported at least seven days post-vaccination and generally resolve within two weeks. However, this was reported as early as four days post-AstraZeneca vaccination. Other dermatological reactions, such as pityriasis rosea-like eruptions and flares of existing cutaneous conditions occurred in mRNA and AstraZeneca recipients but not with Sinopharm. Screening questions may be used to risk stratifying vaccine recipients into low, medium or high risk of developing severe allergic reactions. Skin testing may be considered for high-risk category patients. However, negative skin testing does not rule out a subsequent allergic response. Delayed cutaneous reactions may be misdiagnosed as cellulitis, resulting in unnecessary treatment with antibiotics. such as vitamins, other vaccines, anti-arrhythmics, anti-diabetics, thrombolytics, anti-cancer agents, contraceptives, creams, ointments
{"title":"Cutaneous Reactions after COVID-19 vaccines","authors":"Alicia Wan Yan Poh, S. Teo","doi":"10.52547/vacres.8.1.98","DOIUrl":"https://doi.org/10.52547/vacres.8.1.98","url":null,"abstract":"This article provides an overview of cutaneous reactions after administration of COVID19 vaccines. Cutaneous reactions post COVID-19 trials range from acute and immediate reactions to delayed reactions. The suspected triggers for the hypersensitivity reactions are the inactive ingredients, such as polyethylene glycol in mRNA vaccines and polysorbate 80 in AstraZeneca. Localized or injection-site reactions are generally self-limiting and occur within seven days. Younger, female patients were more likely to report injection-site reactions. Cutaneous reactions after the second dose occurred earlier than after the first dose. Delayed large local reactions or „COVID arms‟ have been reported at least seven days post-vaccination and generally resolve within two weeks. However, this was reported as early as four days post-AstraZeneca vaccination. Other dermatological reactions, such as pityriasis rosea-like eruptions and flares of existing cutaneous conditions occurred in mRNA and AstraZeneca recipients but not with Sinopharm. Screening questions may be used to risk stratifying vaccine recipients into low, medium or high risk of developing severe allergic reactions. Skin testing may be considered for high-risk category patients. However, negative skin testing does not rule out a subsequent allergic response. Delayed cutaneous reactions may be misdiagnosed as cellulitis, resulting in unnecessary treatment with antibiotics. such as vitamins, other vaccines, anti-arrhythmics, anti-diabetics, thrombolytics, anti-cancer agents, contraceptives, creams, ointments","PeriodicalId":52727,"journal":{"name":"Vaccine Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46209388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. Kiani, A. Abedini, Z. Rouhani, Mohammadhossein Banitorfi, A. Saeidi, H. Zaheri
Recently the term vaccine-induced immune thrombotic thrombocytopenia (VITT) used for individual which have thrombotic phenomena followed by ChAdOx1 nCoV-19 vaccine (AstraZeneca) administration against SARS coronavirus. Here we report the 27 years old healthy male and known case of G6PD deficiency which come to emergency department with progressive right calf swallow from 12 days ago and hemoptysis from a day ago. he mentioned he had administrated First dose of AstraZeneca vaccine for 3 weeks ago. He admitted with suspected pulmonary thromboembolism (PTE) followed by Deep vein thrombosis (DVT). In color Doppler study there are dilation in right calf vain with elevated lab measurement d-dimer indicated DVT also in computed tomography angiography (CTA) there are some evidence of filling defect in left pulmonary branch and right inferior lobar artery which represent to PTE.
{"title":"Pulmonary Thromboembolism Followed by Deep Vein Thrombosis In A Young Man With G6PD Deficiency After ChAd0x1 nCoV-19 Vaccine Administration","authors":"A. Kiani, A. Abedini, Z. Rouhani, Mohammadhossein Banitorfi, A. Saeidi, H. Zaheri","doi":"10.52547/vacres.8.1.88","DOIUrl":"https://doi.org/10.52547/vacres.8.1.88","url":null,"abstract":"Recently the term vaccine-induced immune thrombotic thrombocytopenia (VITT) used for individual which have thrombotic phenomena followed by ChAdOx1 nCoV-19 vaccine (AstraZeneca) administration against SARS coronavirus. Here we report the 27 years old healthy male and known case of G6PD deficiency which come to emergency department with progressive right calf swallow from 12 days ago and hemoptysis from a day ago. he mentioned he had administrated First dose of AstraZeneca vaccine for 3 weeks ago. He admitted with suspected pulmonary thromboembolism (PTE) followed by Deep vein thrombosis (DVT). In color Doppler study there are dilation in right calf vain with elevated lab measurement d-dimer indicated DVT also in computed tomography angiography (CTA) there are some evidence of filling defect in left pulmonary branch and right inferior lobar artery which represent to PTE.","PeriodicalId":52727,"journal":{"name":"Vaccine Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46823409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. Namvar, A. Hajizade, S. Nazarian, Davoud Sadeghi, M. R. Akbari, Yousof Tarverdizade
Results: The sub-cloning of the gene was confirmed using PCR reaction. Gene expression analysis showed that the desired protein had a suitable expression. Western blotting analysis confirmed the expression of the recombinant protein. Conclusion: The expressed and purified multi-epitope recombinant protein, containing the main epitopes of the common antigens of pathogenic Shigella species could be achieved as the first step to design a multiepitope vaccine candidate against shigellosis.
{"title":"Design and Recombinant Expression of a multiepitope Vaccine Candidate Against Pathogenic Species of Shigella","authors":"A. Namvar, A. Hajizade, S. Nazarian, Davoud Sadeghi, M. R. Akbari, Yousof Tarverdizade","doi":"10.52547/vacres.8.1.18","DOIUrl":"https://doi.org/10.52547/vacres.8.1.18","url":null,"abstract":"Results: The sub-cloning of the gene was confirmed using PCR reaction. Gene expression analysis showed that the desired protein had a suitable expression. Western blotting analysis confirmed the expression of the recombinant protein. Conclusion: The expressed and purified multi-epitope recombinant protein, containing the main epitopes of the common antigens of pathogenic Shigella species could be achieved as the first step to design a multiepitope vaccine candidate against shigellosis.","PeriodicalId":52727,"journal":{"name":"Vaccine Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42983326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
and compared based on sequence analysis of and genes. Their pathogenicities and determined in the chickens. Groups of were inoculated with 0.5ml chicken-embryonated-derived attenuated FAdV isolates via oral and IP routes and trachea, and gizzard collected at days 3, 7, 14 and 21post-inoculation. Results: Molecular analysis revealed both isolates had 99.1% and 97.3% homologies in the L1 loop region of hexon gene and knob region of fiber gene, respectively. Molecular changes in UPM1137E20 were prominent in the knob of fiber gens with 3 amino acid changes, while for UPM1137CEL35, notable in the L1 loop region with 3 amino acid changes. It was demonstrated that both attenuated isolates are non-pathogenic and safe in commercial broiler chickens. Neither gross nor histopathological lesions were recorded in all tested groups. Both isolates induced high antibody response significantly via intraperitoneal route when compared to the control. Conclusion: UPM1137E20 isolate had a high potential to be further evaluated as a live attenuated vaccine against viral poultry diseases such as IBH.
{"title":"Comparative Sequence Analysis, Pathogenicity and Immunogenicity of Attenuated Fowl Adenovirus Isolates as Experimental Vaccines against Inclusion Body Hepatitis of Commercial Broiler Chickens","authors":"Norfitriah Mohamed Sohaimi, M. Hair-Bejo","doi":"10.52547/vacres.8.1.81","DOIUrl":"https://doi.org/10.52547/vacres.8.1.81","url":null,"abstract":"and compared based on sequence analysis of and genes. Their pathogenicities and determined in the chickens. Groups of were inoculated with 0.5ml chicken-embryonated-derived attenuated FAdV isolates via oral and IP routes and trachea, and gizzard collected at days 3, 7, 14 and 21post-inoculation. Results: Molecular analysis revealed both isolates had 99.1% and 97.3% homologies in the L1 loop region of hexon gene and knob region of fiber gene, respectively. Molecular changes in UPM1137E20 were prominent in the knob of fiber gens with 3 amino acid changes, while for UPM1137CEL35, notable in the L1 loop region with 3 amino acid changes. It was demonstrated that both attenuated isolates are non-pathogenic and safe in commercial broiler chickens. Neither gross nor histopathological lesions were recorded in all tested groups. Both isolates induced high antibody response significantly via intraperitoneal route when compared to the control. Conclusion: UPM1137E20 isolate had a high potential to be further evaluated as a live attenuated vaccine against viral poultry diseases such as IBH.","PeriodicalId":52727,"journal":{"name":"Vaccine Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46246150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
O. Olaolu, H. Kazeem, J. Adamu, T. Markus, T. Woma
examined using Competitive ELISA (c-ELISA) for the presence of specific PPR-N antibodies. Results: The analysed result showed that there was significant difference ( P < 0.05) in the mean PPRV-N specific antibody c-ELISA values (0-13) before vaccination and the percentage competition protective values (> 50%). However, no significant difference ( p > 0.05) post-vaccination in both pregnant and non-pregnant ewes was observed throughout the period of the study with mean PPRV-N specific c-ELISA antibodies of 72-86 and 52-86, respectively. The mean PPRV-N specific antibodies values were maintained within the protective value (> 50 %). The result of this study also showed that there was significant difference ( P < 0.05) with mean PPRV-N specific c-ELISA antibodies (17.3-29.4; 87.5%) of lambs born to vaccinated pregnant Yankassa ewes from 8 weeks. Conclusion: This study showed that vaccination does not affect pregnancy with Nigeria 75/1 strain of PPR vaccine in ewes as there was no record of abortion. There was a rapid PPR maternal antibody decay in lambs from the 8th week of age as it was observed that at age 10 weeks, only 37.5 % of the lambs had protective titre. It is therefore recommended that lambs can be vaccinated at 9 th week to avoid the window of susceptibility to PPR virus infection.
{"title":"Assessment of Peste Des Petits Ruminants Antibodies in Vaccinated Yankasa Pregnant Ewes from Nigeria and the Duration of Maternal Immunity in Their Lambs","authors":"O. Olaolu, H. Kazeem, J. Adamu, T. Markus, T. Woma","doi":"10.52547/vacres.8.1.47","DOIUrl":"https://doi.org/10.52547/vacres.8.1.47","url":null,"abstract":"examined using Competitive ELISA (c-ELISA) for the presence of specific PPR-N antibodies. Results: The analysed result showed that there was significant difference ( P < 0.05) in the mean PPRV-N specific antibody c-ELISA values (0-13) before vaccination and the percentage competition protective values (> 50%). However, no significant difference ( p > 0.05) post-vaccination in both pregnant and non-pregnant ewes was observed throughout the period of the study with mean PPRV-N specific c-ELISA antibodies of 72-86 and 52-86, respectively. The mean PPRV-N specific antibodies values were maintained within the protective value (> 50 %). The result of this study also showed that there was significant difference ( P < 0.05) with mean PPRV-N specific c-ELISA antibodies (17.3-29.4; 87.5%) of lambs born to vaccinated pregnant Yankassa ewes from 8 weeks. Conclusion: This study showed that vaccination does not affect pregnancy with Nigeria 75/1 strain of PPR vaccine in ewes as there was no record of abortion. There was a rapid PPR maternal antibody decay in lambs from the 8th week of age as it was observed that at age 10 weeks, only 37.5 % of the lambs had protective titre. It is therefore recommended that lambs can be vaccinated at 9 th week to avoid the window of susceptibility to PPR virus infection.","PeriodicalId":52727,"journal":{"name":"Vaccine Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44833913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：